Purple Biotech (PPBT) Debt Ratio (2015 - 2016)
Purple Biotech's (PPBT) quarterly Debt Ratio came in at 0.04 in Q4 2016, down 27.64% year-on-year from 0.05 in Q1 2016, and down 27.64% on a QoQ basis from 0.05 in Q4 2015.
Purple Biotech (PPBT) Debt Ratio (2015 - 2016) Analysis & Trends
Purple Biotech (PPBT) has 2 years of Debt Ratio data on file, last reported at 0.04 in Q4 2016.
- On a quarterly basis, Debt Ratio fell 27.64% year-over-year to 0.04 in Q4 2016; TTM through Dec 2016 was 0.04, a 27.64% decrease from a year earlier, with the FY2016 full-year figure at 0.04, down 27.64% from the prior year.
- Debt Ratio for Q4 2016 stood at 0.04, down from 0.05 in the prior quarter.
- Over the last five years, Debt Ratio for PPBT reached as high as 0.05 in Q4 2015 and fell as low as 0.04 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 1.41 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.11 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Purple Biotech | 1.33 Bn | 1.33 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 0.04 |
| Dec 31, 2015 | 0.05 |